83405-70-3

Basic information

• Product Name: Ethyl 5-(tert-butyl)-2H-pyrazole-3-carboxylate
• Synonyms: AKOS BBS-00004492;5-TERT-BUTYL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER;ETHYL 5-TERT-BUTYL-2H-PYRAZOLE-3-CARBOXYLATE;ETHYL 3-(TERT-BUTYL)-1H-PYRAZOLE-5-CARBOXYLATE;ETHYL 3-T-BUTYL-5-PYRAZOLECARBOXYLATE;BUTTPARK 36\06-08;5-tert-Butyl-2H-pyrazole-3-carboxylic acid ethyl;ETHYL 3-TERT-BUTYLPYRAZOLE-5-CARBOXYLATE
• CAS NO: 83405-70-3
• Molecular Formula: C₁₀H₁₆N₂O₂
• Molecular Weight: 196.25
• Mol File: 83405-70-3.mol

Chemical Properties

• Melting Point: 141-144°C
• Boiling Point: 322.3 °C at 760 mmHg
• Flash Point: 148.7 °C
• Appearance: /
• Density: 0.91
• Vapor Pressure: 0.000281mmHg at 25°C
• Refractive Index: 1.5
• CAS DataBase Reference: Ethyl 5-(tert-butyl)-2H-pyrazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 5-(tert-butyl)-2H-pyrazole-3-carboxylate(83405-70-3)
• EPA Substance Registry System: Ethyl 5-(tert-butyl)-2H-pyrazole-3-carboxylate(83405-70-3)

Safety Data

• Safety Statements: 24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 83405-70-3(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C10H16N2O2/c1-5-14-9(13)7-6-8(12-11-7)10(2,3)4/h6H,5H2,1-4H3,(H,11,12)

Upstream product

• 75-97-8 3,3-dimethyl-butan-2-one 
• 37174-98-4 ethyl 4-oxo-5,5-dimethylhexanoate 
• 13395-36-3 ethyl trimethylacetopyruvate 
• 95-92-1 oxalic acid diethyl ester 
• 94122-76-6 ethyl 2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate 
• 302-01-2 hydrazine 
• 623-73-4 diazoacetic acid ethyl ester 
• 917-92-0 3,3-Dimethylbut-1-yne 

Downstream Products

• 682757-38-6 ethyl 3-(1,1-dimethylethyl)-1-ethyl-1H-pyrazole-5-carboxylate 
• 1240311-64-1 5-tert-butyl-1H-pyrazole-3-carboxamide 
• 1231961-65-1 3-(N-methylaminomethyl)-5-tert-butyl-1H-pyrazole dihydrochloride 
• 866588-08-1 3-tert-butyl-1-{4-[(methoxymethoxy)methyl]benzyl}-5-(phenoxymethyl)-1H-pyrazole 
• 865138-45-0 (4-{[3-tert-butyl-5-(phenoxymethyl)-1H-pyrazol-1-yl]methyl}phenyl)methanol 
• 865138-43-8 ethyl 3-tert-butyl-1-{4-[(methoxymethoxy)methyl]benzyl}-1H-pyrazole-5-carboxylate 
• 865138-44-9 (3-tert-butyl-1-{4-[(methoxymethoxy)methyl]benzyl}-1H-pyrazol-5-yl)methanol 
• 1276030-62-6 3-tert-butyl-1H-pyrazole-5-carbaldehyde 
• 1255040-45-9 N-((3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)methyl)-2-(3-fluoro-4-(methylsulphonamido)phenyl)propanamide 
• 1254713-66-0 (3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)methanamine 
• 1254713-61-5 (3-tert-butyl-1-(4-chlorophenyl)-1H-pyrazol-5-yl)methanamine 
• 1349979-20-9 C₈H₁₅N₃ 
• 1255040-43-7 N-((3-tert-butyl-1-(3-chloro-4-fluorophenyl)-1H-pyrazol-5-yl)methyl)-2-(3-fluoro-4-(methylsulphonamido)phenyl)propanamide 
• 1255040-42-6 (S)-N-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methyl)-2-(3-fluoro-4-(methylsulphonamido)phenyl)propanamide 

Relevant articles and documents

From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis

Synthetic cannabinoids, as exemplified by SDB-001 (1), bind to both CB1 and CB2 receptors and exert cannabimimetic effects similar to (-)-trans-Δ9-tetrahydrocannabinol, the main psychoactive component present in the cannabis plant. As CB1 receptor ligands were found to have severe adverse psychiatric effects, increased attention was turned to exploiting the potential therapeutic value of the CB2 receptor. In our efforts to discover novel and selective CB2 receptor agonists, 1 was selected as a starting point for hit molecule identification and a class of 1H-pyrazole-3-carboxamide derivatives were thus designed, synthesized, and biologically evaluated. Systematic structure-activity relationship investigations resulted in the identification of the most promising compound 66 as a selective CB2 receptor agonist with favorable pharmacokinetic profiles. Especially, 66 treatment significantly attenuated dermal inflammation and fibrosis in a bleomycin-induced mouse model of systemic sclerosis, supporting that CB2 receptor agonists might serve as potential therapeutics for treating systemic sclerosis.

The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist

The development of selective CB2 receptor agonists is a promising therapeutic approach for the treatment of inflammatory diseases, without CB1 receptor mediated psychoactive side effects. Preliminary structure-activity relationship studies on pyrazoylidene benzamide agonists revealed the -ylidene benzamide moiety was crucial for functional activity at the CB2 receptor. A small library of compounds with varying linkage moieties between the pyrazole and substituted phenyl group has culminated in the discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine agonist 19 (CB2R EC50 = 19 nM, CB1R EC50 > 10 μM). Docking studies have revealed key structural features of the linkage group that are important for potent functional activity.

Nitrogen-containing five-membered heteroaromatic compound and preparation method and application thereof

The invention discloses a nitrogen-containing five-membered heteroaromatic compound as shown in structural formulae (I) and (II), a medicinal derivative, a hydrate, a composition containing the nitrogen-containing five-membered heteroaromatic compound and a preparation method thereof. The invention also disclose an application of the compound as a drug and as a cannabinoid acceptor adjustor for preventing and treating ache, inflammation, immune diseases and central nervous system diseases and the like.

The First Example of Azole-Fused Cyclic Anhydride Reacting in the Castagnoli-Cushman Way

Pyrazole-fused cyclic anhydrides have been employed for the first time as the Castagnoli-Cushman reaction partners to produce hitherto unknown 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5- a ]pyrazine-7-carboxylates in remarkably convenient and speedy fashion. At

Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP) = 0.1 nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.

N-Substituted pyrazole-3-carboxamides as inhibitors of human 15-lipoxygenase

High-throughput screening was used to find selective inhibitors of human 15-lipoxygenase-1 (15-LOX-1). One hit, a 1-benzoyl substituted pyrazole-3-carboxanilide (1a), was used as a starting point in a program to develop potent and selective 15-LOX-1 inhibitors.

Synthesis of 3-aminomethyl-substituted pyrazoles and isoxazoles

A series of new 3-(aminomethyl)pyrazoles and 3-(aminomethyl)isoxazoles was synthesized along a route involving the formation as key intermediates of esters of 5-substituted 1H-pyrazole-3-carboxylic and 1H-isoxazole-3-carboxylic acids. All compounds obtain

PYRAZOLEPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

The present invention relates to compounds that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation, and particular

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

The present invention relates to compounds that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation, and particular

Novel compounds useful for the treatment of degenerative and inflammatory diseases

The present invention relates to compounds that are inhibitors of PDE1A, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.